CEA and Estrogen Receptor Status in Breast Cancer
Author Information
Author(s): FA Mauri, O Caffo, S Veronese, P Verderio, P Boracchi, M Bonzanini, N Rossi, G Perrone, P Dalla Palma, M Barbareschi
Primary Institution: SS Trinita Hospital, Borgomanero; S Chiara Hospital, Trento; Niguarda Hospital, Milan; University of Milan; National Cancer Institute of Milan, Italy
Hypothesis
The study aims to evaluate the prognostic value of CEA immunohistochemical expression in breast carcinomas in relation to estrogen receptor status.
Conclusion
CEA immunoreactivity was not found to be prognostically relevant in breast cancer patients, with nodal status and tumor size being the most important prognostic markers.
Supporting Evidence
- CEA immunoreactivity was seen in 45% of breast carcinoma cases.
- The median follow-up duration was 84 months.
- Univariate analysis showed no significant association between CEA score and clinical outcomes.
- Traditional prognostic markers like nodal status and tumor size were more predictive than CEA.
- ER status was a significant prognostic factor in node-positive patients receiving hormonal therapy.
Takeaway
The study looked at a marker called CEA in breast cancer but found it didn't help predict how patients would do; instead, things like lymph node involvement and tumor size were more important.
Methodology
The study involved immunohistochemical analysis of CEA expression in 252 breast carcinoma patients, with follow-up data collected over several years.
Limitations
The study did not find a significant association between CEA expression and other clinicopathological features, which may limit its applicability.
Participant Demographics
{"age":{"min":20,"median":54.5,"max":82},"gender":"female","tumor_types":{"ductal":217,"lobular":12,"other":23}}
Want to read the original?
Access the complete publication on the publisher's website